Scott K. Fridkin, MD; Jonathan R. Edwards, MS; Jeanne M. Courval, PhD; Holly Hill, MD, PhD; Fred C. Tenover, PhD; Rachel Lawton, MPH; Robert P. Gaynes, MD; John E. McGowan Jr., MD; for the Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project and the National Nosocomial Infections Surveillance (NNIS) System Hospitals
Acknowledgments: The authors thank the infection control, pharmacy, and microbiology personnel from the participating ICARE hospitals of NNIS for reporting the data for this study. In addition, they wish to recognize the contributions of Lennox Archibald, MD, Erica R. Pryor, RN, PhD, Carol McClay, RN, and Christine D. Steward, MPH, for coordinating submission and processing of data from the participating hospitals. They also thank Harland Austin, PhD, for expert statistical support.
Grant Support: In part by grants to the Rollins School of Public Health of Emory University for Phases 2 and 3 of Project ICARE by AstraZeneca Pharmaceuticals, Wilmington, Delaware, Pfizer, Inc. (New York, New York), and Roche Laboratories (Nutley, New Jersey) as full sponsors; and Aventis Pharma (formerly Rhône–Poulenc Rorer) (Collegeville, Pennsylvania), the National Foundation for Infectious Diseases (Bethesda, Maryland), The American Society for Health Systems Pharmacists Research and Education Foundation (Bethesda, Maryland), Kimberly-Clark Corp. (Roswell, Georgia), and Bayer Corp., Pharmaceuticals Division (West Haven, Connecticut), as partial sponsors.
Requests for Single Reprints: Scott K. Fridkin, MD, Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, MS A-35, 1600 Clifton Road, Atlanta, GA 30333; e-mail, email@example.com.
Current Author Addresses: Dr. Fridkin: Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, MS A-35, 1600 Clifton Road, Atlanta, GA 30333.
Dr. Courvel: Division of Parasitic Diseases/Immunology, Centers for Disease Control and Prevention, MS F-12, 4770 Buford Highway, Chamblee, GA 30341.
Mr. Edwards, Dr. Gaynes, and Ms. Lawton: Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, MS E-55, 1600 Clifton Road, Atlanta, GA 30333.
Drs. McGowan and Hill: Epidemiology Department, Rollins School of Public Health, Emory University, 1518 Clifton Road, Atlanta, GA 30322.
Dr. Tenover: Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, MS G-08, 1600 Clifton Road, Atlanta, GA 30333.
Author Contributions: Conception and design: S.K. Fridkin, J.R. Edwards, J.E. McGowan.
Analysis and interpretation of the data: S.K. Fridkin, J.R. Edwards, J.M. Courval, H. Hill, F.C. Tenover, J.E. McGowan.
Drafting of the article: S.K. Fridkin, J.M. Courval, J.E. McGowan.
Critical revision of the article for important intellectual content: S.K. Fridkin, J.R. Edwards, H. Hill, F.C. Tenover, J.E. McGowan.
Final approval of the article: S.K. Fridkin, J.R. Edwards.
Statistical expertise: S.K. Fridkin, J.R. Edwards, J.M. Courval, H. Hill.
Administrative, technical, or logistic support: S.K. Fridkin, J.R. Edwards, F.C. Tenover, R.M. Lawton.
Collection and assembly of data: S.K. Fridkin, J.R. Edwards, R.M. Lawton.
Patient-specific risk factors for acquisition of vancomycin-resistant enterococci (VRE) among hospitalized patients are becoming well defined. However, few studies have reported data on the institutional risk factors, including rates of antimicrobial use, that predict rates of VRE. Identifying modifiable institutional factors can advance quality-improvement efforts to minimize hospital-acquired infections with VRE.
To determine the independent importance of any association between antimicrobial use and risk factors for nosocomial infection on rates of VRE in intensive care units (ICUs).
Prospective ecologic study.
126 adult ICUs from 60 U.S. hospitals from January 1996 through July 1999.
All patients admitted to participating ICUs.
Monthly use of antimicrobial agents (defined daily doses per 1000 patient-days), nosocomial infection rates, and susceptibilities of all tested enterococci isolated from clinical cultures.
Prevalence of VRE (median, 10%; range, 0% to 59%) varied by type of ICU and by teaching status and size of the hospital. Prevalence of VRE was strongly associated with VRE prevalence among inpatient non-ICU areas and outpatient areas in the hospital, ventilator-days per 1000 patient-days, and rate of parenteral vancomycin use. In a weighted linear regression model controlling for type of ICU and rates of VRE among non-ICU inpatient areas, rates of vancomycin use (P < 0.001) and third-generation cephalosporin use (P = 0.02) were independently associated with VRE prevalence.
Higher rates of vancomycin or third-generation cephalosporin use were associated with increased prevalence of VRE, independent of other ICU characteristics and the endemic VRE prevalence elsewhere in the hospital. Decreasing the use rates of these antimicrobial agents could reduce rates of VRE in ICUs.
Table 1. Class, Grouping, and Defined Daily Dose of Antimicrobial Agents
Table 2. Selected Characteristics (Median Values) of 126 Intensive Care Units, according to Unit Type
Correlation of the rate of parenteral vancomycin (defined daily doses per 1000 patient-days) and the prevalence of vancomycin-resistant enterococci (percentage of enterococci that are vancomycin resistant) in 126 intensive care units.PrP
Table 3. Independent Predictors of Intensive Care Unit–Specific Prevalence of Vancomycin-Resistant Enterococci
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Fridkin SK, Edwards JR, Courval JM, Hill H, Tenover FC, Lawton R, et al. The Effect of Vancomycin and Third-Generation Cephalosporins on Prevalence of Vancomycin-Resistant Enterococci in 126 U.S. Adult Intensive Care Units. Ann Intern Med. 2001;135:175–183. doi: 10.7326/0003-4819-135-3-200108070-00009
Download citation file:
Published: Ann Intern Med. 2001;135(3):175-183.
Hospital Medicine, Pulmonary/Critical Care.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use